Loading…

Progress Toward Control of Rubella and Prevention of Congenital Rubella Syndrome—Worldwide, 2009

Rubella, usually a mild rash illness in children and adults, can cause serious consequences when a pregnant woman is infected, particularly in early pregnancy. These serious consequences include miscarriage, fetal death or an infant born with birth defects (i.e., congenital rubella syndrome (CRS))....

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2011-07, Vol.204 (suppl_1), p.S24-S27
Main Authors: Reef, S. E., Strebel, P., Dabbagh, A., Gacic-Dobo, M., Cochi, S.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c413t-9d25a2256c1bc2ace68b70e88246dd8e0ed13e067db0f9fdfbd7f4e29b9bb3e93
cites cdi_FETCH-LOGICAL-c413t-9d25a2256c1bc2ace68b70e88246dd8e0ed13e067db0f9fdfbd7f4e29b9bb3e93
container_end_page S27
container_issue suppl_1
container_start_page S24
container_title The Journal of infectious diseases
container_volume 204
creator Reef, S. E.
Strebel, P.
Dabbagh, A.
Gacic-Dobo, M.
Cochi, S.
description Rubella, usually a mild rash illness in children and adults, can cause serious consequences when a pregnant woman is infected, particularly in early pregnancy. These serious consequences include miscarriage, fetal death or an infant born with birth defects (i.e., congenital rubella syndrome (CRS)). The primary purpose for rubella vaccination is the prevention of congenital rubella infection including CRS. Since 1969, several rubella virus vaccines have been licensed for use; however, until the 1990s, use of rubella-containing vaccine (RCV) was limited primarily to developed countries. In 1996, it was estimated that 110,000 infants with CRS were born annually in developing countries. In 2000, the first World Health Organization rubella vaccine position paper was published to guide introduction of RCV in national childhood immunization schedules. From 1996 to 2009, the number of countries that introduced RCV into their national routine childhood immunization programs increased by 57% from 83 countries in 1996 to 130 countries in 2009. In addition, three of the six WHO regions established rubella control and CRS prevention goals: Region of the Americas and Europe rubella elimination by 2010 and 2015, respectively, and Western Pacific Region-accelerated rubella control and CRS prevention by 2015. Also, during this time period, the number of rubella cases reported decreased from 670,894 in 2000 to 121,344 in 2009. Rubella control and prevention of CRS can be accelerated by integrating with current global measles mortality reduction and regional elimination activities.
doi_str_mv 10.1093/infdis/jir155
format article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_872436007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>41230441</jstor_id><oup_id>10.1093/infdis/jir155</oup_id><sourcerecordid>41230441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-9d25a2256c1bc2ace68b70e88246dd8e0ed13e067db0f9fdfbd7f4e29b9bb3e93</originalsourceid><addsrcrecordid>eNqF0L1OwzAUhmELgaAURkZQNhgIPbYTJx5RxZ9UiQqKGKM4PqlSJXGxE6puXARXyJWQKqUrkwc_-mS_hJxRuKEg-aioc1240aKwNAz3yICGPPKFoHyfDAAY82ks5RE5dm4BAAEX0SE5YlR0RMQDoqbWzC06583MKrXaG5u6sab0TO69tArLMvXSWntTi59YN4WpNzcdmmNdNGm5Q6_rWltT4c_X97uxpV4VGq89BiBPyEGelg5Pt-eQvN3fzcaP_uT54Wl8O_GzgPLGl5qFKWOhyKjKWJqhiFUEGMcsEFrHCKgpRxCRVpDLXOdKR3mATCqpFEfJh-Sy311a89Gia5KqcNnmcTWa1iVxxLrvA0Sd9HuZWeOcxTxZ2qJK7TqhkGyqJn3VpK_a-Yvtcqsq1Dv9l7EDVz0w7fLfrfOeLlxj7A4HlHEIuhC_FjyOiw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>872436007</pqid></control><display><type>article</type><title>Progress Toward Control of Rubella and Prevention of Congenital Rubella Syndrome—Worldwide, 2009</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Oxford Journals Online</source><creator>Reef, S. E. ; Strebel, P. ; Dabbagh, A. ; Gacic-Dobo, M. ; Cochi, S.</creator><creatorcontrib>Reef, S. E. ; Strebel, P. ; Dabbagh, A. ; Gacic-Dobo, M. ; Cochi, S.</creatorcontrib><description>Rubella, usually a mild rash illness in children and adults, can cause serious consequences when a pregnant woman is infected, particularly in early pregnancy. These serious consequences include miscarriage, fetal death or an infant born with birth defects (i.e., congenital rubella syndrome (CRS)). The primary purpose for rubella vaccination is the prevention of congenital rubella infection including CRS. Since 1969, several rubella virus vaccines have been licensed for use; however, until the 1990s, use of rubella-containing vaccine (RCV) was limited primarily to developed countries. In 1996, it was estimated that 110,000 infants with CRS were born annually in developing countries. In 2000, the first World Health Organization rubella vaccine position paper was published to guide introduction of RCV in national childhood immunization schedules. From 1996 to 2009, the number of countries that introduced RCV into their national routine childhood immunization programs increased by 57% from 83 countries in 1996 to 130 countries in 2009. In addition, three of the six WHO regions established rubella control and CRS prevention goals: Region of the Americas and Europe rubella elimination by 2010 and 2015, respectively, and Western Pacific Region-accelerated rubella control and CRS prevention by 2015. Also, during this time period, the number of rubella cases reported decreased from 670,894 in 2000 to 121,344 in 2009. Rubella control and prevention of CRS can be accelerated by integrating with current global measles mortality reduction and regional elimination activities.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jir155</identifier><identifier>PMID: 21666168</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Childhood ; Congenital rubella syndrome ; Female ; Global Health ; Humans ; Immunization schedules ; Infections ; Measles ; Population Surveillance ; Pregnancy ; PUBLIC HEALTH IMPORTANCE OF MEASLES AND RUBELLA ; Public Policy ; Rubella ; Rubella - prevention &amp; control ; Rubella Syndrome, Congenital - prevention &amp; control ; Rubella Vaccine - administration &amp; dosage ; Rubella Vaccine - economics ; Rubella vaccines ; Rubella virus ; Surveillance ; Vaccination ; World Health Organization</subject><ispartof>The Journal of infectious diseases, 2011-07, Vol.204 (suppl_1), p.S24-S27</ispartof><rights>Copyright © 2011 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011. 2011</rights><rights>Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-9d25a2256c1bc2ace68b70e88246dd8e0ed13e067db0f9fdfbd7f4e29b9bb3e93</citedby><cites>FETCH-LOGICAL-c413t-9d25a2256c1bc2ace68b70e88246dd8e0ed13e067db0f9fdfbd7f4e29b9bb3e93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/41230441$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/41230441$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21666168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reef, S. E.</creatorcontrib><creatorcontrib>Strebel, P.</creatorcontrib><creatorcontrib>Dabbagh, A.</creatorcontrib><creatorcontrib>Gacic-Dobo, M.</creatorcontrib><creatorcontrib>Cochi, S.</creatorcontrib><title>Progress Toward Control of Rubella and Prevention of Congenital Rubella Syndrome—Worldwide, 2009</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Rubella, usually a mild rash illness in children and adults, can cause serious consequences when a pregnant woman is infected, particularly in early pregnancy. These serious consequences include miscarriage, fetal death or an infant born with birth defects (i.e., congenital rubella syndrome (CRS)). The primary purpose for rubella vaccination is the prevention of congenital rubella infection including CRS. Since 1969, several rubella virus vaccines have been licensed for use; however, until the 1990s, use of rubella-containing vaccine (RCV) was limited primarily to developed countries. In 1996, it was estimated that 110,000 infants with CRS were born annually in developing countries. In 2000, the first World Health Organization rubella vaccine position paper was published to guide introduction of RCV in national childhood immunization schedules. From 1996 to 2009, the number of countries that introduced RCV into their national routine childhood immunization programs increased by 57% from 83 countries in 1996 to 130 countries in 2009. In addition, three of the six WHO regions established rubella control and CRS prevention goals: Region of the Americas and Europe rubella elimination by 2010 and 2015, respectively, and Western Pacific Region-accelerated rubella control and CRS prevention by 2015. Also, during this time period, the number of rubella cases reported decreased from 670,894 in 2000 to 121,344 in 2009. Rubella control and prevention of CRS can be accelerated by integrating with current global measles mortality reduction and regional elimination activities.</description><subject>Childhood</subject><subject>Congenital rubella syndrome</subject><subject>Female</subject><subject>Global Health</subject><subject>Humans</subject><subject>Immunization schedules</subject><subject>Infections</subject><subject>Measles</subject><subject>Population Surveillance</subject><subject>Pregnancy</subject><subject>PUBLIC HEALTH IMPORTANCE OF MEASLES AND RUBELLA</subject><subject>Public Policy</subject><subject>Rubella</subject><subject>Rubella - prevention &amp; control</subject><subject>Rubella Syndrome, Congenital - prevention &amp; control</subject><subject>Rubella Vaccine - administration &amp; dosage</subject><subject>Rubella Vaccine - economics</subject><subject>Rubella vaccines</subject><subject>Rubella virus</subject><subject>Surveillance</subject><subject>Vaccination</subject><subject>World Health Organization</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqF0L1OwzAUhmELgaAURkZQNhgIPbYTJx5RxZ9UiQqKGKM4PqlSJXGxE6puXARXyJWQKqUrkwc_-mS_hJxRuKEg-aioc1240aKwNAz3yICGPPKFoHyfDAAY82ks5RE5dm4BAAEX0SE5YlR0RMQDoqbWzC06583MKrXaG5u6sab0TO69tArLMvXSWntTi59YN4WpNzcdmmNdNGm5Q6_rWltT4c_X97uxpV4VGq89BiBPyEGelg5Pt-eQvN3fzcaP_uT54Wl8O_GzgPLGl5qFKWOhyKjKWJqhiFUEGMcsEFrHCKgpRxCRVpDLXOdKR3mATCqpFEfJh-Sy311a89Gia5KqcNnmcTWa1iVxxLrvA0Sd9HuZWeOcxTxZ2qJK7TqhkGyqJn3VpK_a-Yvtcqsq1Dv9l7EDVz0w7fLfrfOeLlxj7A4HlHEIuhC_FjyOiw</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Reef, S. E.</creator><creator>Strebel, P.</creator><creator>Dabbagh, A.</creator><creator>Gacic-Dobo, M.</creator><creator>Cochi, S.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110701</creationdate><title>Progress Toward Control of Rubella and Prevention of Congenital Rubella Syndrome—Worldwide, 2009</title><author>Reef, S. E. ; Strebel, P. ; Dabbagh, A. ; Gacic-Dobo, M. ; Cochi, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-9d25a2256c1bc2ace68b70e88246dd8e0ed13e067db0f9fdfbd7f4e29b9bb3e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Childhood</topic><topic>Congenital rubella syndrome</topic><topic>Female</topic><topic>Global Health</topic><topic>Humans</topic><topic>Immunization schedules</topic><topic>Infections</topic><topic>Measles</topic><topic>Population Surveillance</topic><topic>Pregnancy</topic><topic>PUBLIC HEALTH IMPORTANCE OF MEASLES AND RUBELLA</topic><topic>Public Policy</topic><topic>Rubella</topic><topic>Rubella - prevention &amp; control</topic><topic>Rubella Syndrome, Congenital - prevention &amp; control</topic><topic>Rubella Vaccine - administration &amp; dosage</topic><topic>Rubella Vaccine - economics</topic><topic>Rubella vaccines</topic><topic>Rubella virus</topic><topic>Surveillance</topic><topic>Vaccination</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reef, S. E.</creatorcontrib><creatorcontrib>Strebel, P.</creatorcontrib><creatorcontrib>Dabbagh, A.</creatorcontrib><creatorcontrib>Gacic-Dobo, M.</creatorcontrib><creatorcontrib>Cochi, S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reef, S. E.</au><au>Strebel, P.</au><au>Dabbagh, A.</au><au>Gacic-Dobo, M.</au><au>Cochi, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progress Toward Control of Rubella and Prevention of Congenital Rubella Syndrome—Worldwide, 2009</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>204</volume><issue>suppl_1</issue><spage>S24</spage><epage>S27</epage><pages>S24-S27</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Rubella, usually a mild rash illness in children and adults, can cause serious consequences when a pregnant woman is infected, particularly in early pregnancy. These serious consequences include miscarriage, fetal death or an infant born with birth defects (i.e., congenital rubella syndrome (CRS)). The primary purpose for rubella vaccination is the prevention of congenital rubella infection including CRS. Since 1969, several rubella virus vaccines have been licensed for use; however, until the 1990s, use of rubella-containing vaccine (RCV) was limited primarily to developed countries. In 1996, it was estimated that 110,000 infants with CRS were born annually in developing countries. In 2000, the first World Health Organization rubella vaccine position paper was published to guide introduction of RCV in national childhood immunization schedules. From 1996 to 2009, the number of countries that introduced RCV into their national routine childhood immunization programs increased by 57% from 83 countries in 1996 to 130 countries in 2009. In addition, three of the six WHO regions established rubella control and CRS prevention goals: Region of the Americas and Europe rubella elimination by 2010 and 2015, respectively, and Western Pacific Region-accelerated rubella control and CRS prevention by 2015. Also, during this time period, the number of rubella cases reported decreased from 670,894 in 2000 to 121,344 in 2009. Rubella control and prevention of CRS can be accelerated by integrating with current global measles mortality reduction and regional elimination activities.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>21666168</pmid><doi>10.1093/infdis/jir155</doi></addata></record>
fulltext fulltext
identifier ISSN: 0022-1899
ispartof The Journal of infectious diseases, 2011-07, Vol.204 (suppl_1), p.S24-S27
issn 0022-1899
1537-6613
language eng
recordid cdi_proquest_miscellaneous_872436007
source JSTOR Archival Journals and Primary Sources Collection; Oxford Journals Online
subjects Childhood
Congenital rubella syndrome
Female
Global Health
Humans
Immunization schedules
Infections
Measles
Population Surveillance
Pregnancy
PUBLIC HEALTH IMPORTANCE OF MEASLES AND RUBELLA
Public Policy
Rubella
Rubella - prevention & control
Rubella Syndrome, Congenital - prevention & control
Rubella Vaccine - administration & dosage
Rubella Vaccine - economics
Rubella vaccines
Rubella virus
Surveillance
Vaccination
World Health Organization
title Progress Toward Control of Rubella and Prevention of Congenital Rubella Syndrome—Worldwide, 2009
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T07%3A50%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progress%20Toward%20Control%20of%20Rubella%20and%20Prevention%20of%20Congenital%20Rubella%20Syndrome%E2%80%94Worldwide,%202009&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Reef,%20S.%20E.&rft.date=2011-07-01&rft.volume=204&rft.issue=suppl_1&rft.spage=S24&rft.epage=S27&rft.pages=S24-S27&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jir155&rft_dat=%3Cjstor_proqu%3E41230441%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c413t-9d25a2256c1bc2ace68b70e88246dd8e0ed13e067db0f9fdfbd7f4e29b9bb3e93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=872436007&rft_id=info:pmid/21666168&rft_jstor_id=41230441&rft_oup_id=10.1093/infdis/jir155&rfr_iscdi=true